424 related articles for article (PubMed ID: 27279652)
1. RANK-RANKL signalling in cancer.
Renema N; Navet B; Heymann MF; Lezot F; Heymann D
Biosci Rep; 2016 Aug; 36(4):. PubMed ID: 27279652
[TBL] [Abstract][Full Text] [Related]
2. The receptor activator of nuclear factor κΒ ligand receptor leucine-rich repeat-containing G-protein-coupled receptor 4 contributes to parathyroid hormone-induced vascular calcification.
Carrillo-López N; Martínez-Arias L; Alonso-Montes C; Martín-Carro B; Martín-Vírgala J; Ruiz-Ortega M; Fernández-Martín JL; Dusso AS; Rodriguez-García M; Naves-Díaz M; Cannata-Andía JB; Panizo S
Nephrol Dial Transplant; 2021 Mar; 36(4):618-631. PubMed ID: 33367746
[TBL] [Abstract][Full Text] [Related]
3. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
Liu W; Zhang X
Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
[TBL] [Abstract][Full Text] [Related]
4. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
5. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
6. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
7. The functions of the avian receptor activator of NF-κB ligand (RANKL) and its receptors, RANK and osteoprotegerin, are evolutionarily conserved.
Sutton KM; Hu T; Wu Z; Siklodi B; Vervelde L; Kaiser P
Dev Comp Immunol; 2015 Jul; 51(1):170-84. PubMed ID: 25796577
[TBL] [Abstract][Full Text] [Related]
8. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
9. Expression Profiling of Receptor-Activator of Nuclear Factor-Kappa B Ligand in Soft Tissue Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Oike N; Sasaki T; Hatano H; Ohashi R; Umezu H; Ajioka Y; Endo N
Tohoku J Exp Med; 2019 Jun; 248(2):87-97. PubMed ID: 31189751
[TBL] [Abstract][Full Text] [Related]
10. Effects of icariin on the regulation of the OPG-RANKL-RANK system are mediated through the MAPK pathways in IL-1β-stimulated human SW1353 chondrosarcoma cells.
Wang Z; Ding L; Zhang S; Jiang T; Yang Y; Li R
Int J Mol Med; 2014 Dec; 34(6):1720-6. PubMed ID: 25270538
[TBL] [Abstract][Full Text] [Related]
11. Expression and Distribution of Receptor Activator of Nuclear Factor Kappa B, Receptor Activator of Nuclear Factor Kappa B Ligand, and Osteoprotegerin in Periradicular Cysts.
Armada L; Marotta Pdos S; Pires FR; Siqueira JF
J Endod; 2015 Aug; 41(8):1281-7. PubMed ID: 25956608
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer.
Peng X; Guo W; Ren T; Lou Z; Lu X; Zhang S; Lu Q; Sun Y
PLoS One; 2013; 8(3):e58361. PubMed ID: 23516466
[TBL] [Abstract][Full Text] [Related]
13. Effects of Wenyangbushen formula on the expression of VEGF, OPG, RANK and RANKL in rabbits with steroid-induced femoral head avascular necrosis.
Song HM; Wei YC; Li N; Wu B; Xie N; Zhang KM; Wang SZ; Wang HM
Mol Med Rep; 2015 Dec; 12(6):8155-61. PubMed ID: 26496816
[TBL] [Abstract][Full Text] [Related]
14. OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in mice.
Shimamura M; Nakagami H; Osako MK; Kurinami H; Koriyama H; Zhengda P; Tomioka H; Tenma A; Wakayama K; Morishita R
Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8191-6. PubMed ID: 24847069
[TBL] [Abstract][Full Text] [Related]
15. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
[TBL] [Abstract][Full Text] [Related]
16. Expression profile of osteoprotegerin, RANK and RANKL genes in the femoral head of patients with avascular necrosis.
Samara S; Dailiana Z; Chassanidis C; Koromila T; Papatheodorou L; Malizos KN; Kollia P
Exp Mol Pathol; 2014 Feb; 96(1):9-14. PubMed ID: 24200492
[TBL] [Abstract][Full Text] [Related]
17. Importance of osteoprotegrin and receptor activator of nuclear factor κB in breast cancer response to hepatocyte growth factor and the bone microenvironment in vitro.
Owen S; Sanders AJ; Mason MD; Jiang WG
Int J Oncol; 2016 Mar; 48(3):919-28. PubMed ID: 26781475
[TBL] [Abstract][Full Text] [Related]
18. RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease.
Christoph F; König F; Lebentrau S; Jandrig B; Krause H; Strenziok R; Schostak M
World J Urol; 2018 Feb; 36(2):187-192. PubMed ID: 29204705
[TBL] [Abstract][Full Text] [Related]
19. CCN2 enhances RANKL-induced osteoclast differentiation via direct binding to RANK and OPG.
Aoyama E; Kubota S; Khattab HM; Nishida T; Takigawa M
Bone; 2015 Apr; 73():242-8. PubMed ID: 25554597
[TBL] [Abstract][Full Text] [Related]
20. Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases.
Milone F; Pivonello C; Cariati F; Sarnataro M; Ramundo V; Marotta V; Jann H; Pape UF; Wiedenmann B; Colao A; Pavel M; Faggiano A
Biomarkers; 2013 Mar; 18(2):121-5. PubMed ID: 23336103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
